Experienced Direction

With a vision for improving breast imaging for all women, our Board of Directors shares our passion in developing new technology that breaks the barriers in breast cancer detection. Their confidence in our team members, alignment with our objectives, and on-going support provide a strong foundation that propels our team forward in our quest to change the landscape of breast imaging. 

  • Paul McCreadie, Chairman
    Managing Director, Arboretum Ventures

    Mr. McCreadie is a Managing Director at Arboretum Ventures, a healthcare focused venture capital firm located in Ann Arbor, Michigan. Paul is responsible for sourcing and leading new investments in promising Medical Technology and Health IT companies. He led Arboretum’s investments into Delphinus Medical Technologies, Wellfount Pharmacy, ArborMetrix, and Advance Medical and currently serves on the Board of Directors of each company. He is the former Chief Operating Officer for CerviLenz, a portfolio company based in Ohio, where he led the re-design of the company’s first commercial product from concept to launch. Prior to joining Arboretum in 2006, Paul worked at Ford Motor Company for eight years in product development, manufacturing, and business strategy. Paul earned a BS and MS in Mechanical Engineering from the University of Michigan and an MBA from the Ross School of Business at the University of Michigan.

  • Hugo Braun, Director
    Partner & Co-founder, North Coast Technology Investors

    Mr. Braun is a partner and co-founder of North Coast Technology Investors, a Michigan-based venture capital firm with $100 million under management. North Coast focuses on early stage investments in IT, advanced materials and life sciences. Prior to North Coast, Mr. Braun worked in San Francisco co-managing Bank of America’s venture capital portfolio. Previously, he was a management consultant with Strategic Planning Associates, a spin-off of the Boston Consulting Group based in Washington, DC. He holds an M.S. in Management from the Sloan School of Management at MIT and a B.A. in Economics from Yale University. Hugo joined the Delphinus Board of Directors at the time of its formation in May 2010.

  • Mark J. Forchette, Director
    President & CEO, Delphinus Medical Technologies, Inc.

    Mr. Forchette is an accomplished medical technology executive with demonstrated success transforming industries and driving breakthrough technologies to market leadership. Prior to joining Delphinus, Forchette was president and chief executive officer of OptiMedica Corporation, an ophthalmic medical device company that dramatically changed the standard of care in retina, glaucoma and cataract. He led the start-up venture through development and growth, successfully completed multiple rounds of financing, and oversaw the company’s acquisition by Abbott Laboratories in 2013. He began his career in the medical technology industry as a sales representative at Greishaber and Company, Inc., where he ultimately became vice president of U.S. sales and marketing and led the company through its acquisition by Alcon. During his tenure at Alcon, he steered the tactical integration of Grieshaber, advanced to Vice President of vitreoretinal sales and global marketing, and led the retina portfolio through substantial market share gain. Mr. Forchette has a bachelor’s degree in marketing from Auburn University and completed the Harvard Program for Management Development. He is currently on the Dean’s Advisory Board of the Harbert College of Business at Auburn and is a member of the board of directors of VisionCare Technologies in Saratoga, California.

  • Michael Fulton, M.D., Director
    Managing Director, Hopen Life Sciences Ventures

    Dr. Fulton has over 20 years of experience in the life sciences space, including 14 years as a successful early stage investor and entrepreneur. Prior to joining Hopen, Mike served in the roles of founder, director, and CEO at startup medical device and services companies, including Lanx, Inc., the second largest private company in the $7B spinal implant market. As CEO of Lanx, he built the organization from a single employee, pre-revenue company into an international corporation with over 200 employees. His accomplishments included raising over $50M in equity and venture debt, building a world-class team of medical device professionals, and launching an innovative fusion product that advanced a new paradigm in spinal treatment. Mike also played a key leadership role, served on the Board, and helped raise over $46M of equity for ProNerve, LLC, an Intraoperative Monitoring company he co-founded in 2007. Mike is an inventor of multiple neurosurgical and spinal devices with over 50 issued and pending U.S. and international patents. He received his B.A. from Northwestern University, his M.D. from Cornell University Medical College, and completed two years of neurosurgery residency at the Cleveland Clinic.

  • Michael Gross, Director
    Managing Director, Beringea, LLC

    Mr. Gross is Managing Director at Beringea, LLC and is responsible for investment sourcing, deal execution and portfolio management, with a focus on healthcare, technology enabled services, and sustainability. He joined the Board of Directors for Delphinus Medical Technologies in 2010. Within the Beringea portfolio of companies, he serves on the boards of Molecular Imaging, InTouch Health, Intervention Insights, Xanitos, Freeosk, and Fiber By-Products, and is a board observer for MedVantx. Previous portfolio companies include Pioneer Surgical Technology (acquired by RTI Biologics), Relume Technology (acquired by Revolution Lighting), and Ecosynthetix (TSX: ECO). Prior to joining Beringea, Mr. Gross was vice president of investment banking with P&M Corporate Finance as well as the investment banking group at Stout Risius Ross, Inc. He is a CFA charterholder and earned a B.A. in Finance from Michigan State University.

  • Ronald Ho, Director
    Medical Device Industry Executive

    Mr. Ho’s career has included multiple executive positions spanning 25 years within the medical device industry. He was President and CEO of U-Systems from 2008-2013, developer of the somo•V automated whole breast ultrasound system. During his tenure, the company completed the largest clinical trial of its kind and achieved a first and only FDA approval for a breast ultrasound screening indication. Following this, Mr. Ho directed U-Systems through the successful acquisition by GE Healthcare, occurring in November 2012. Prior to U-Systems, he served as President and CEO of Metron Systems, guiding the technology start-up to develop and commercialize advanced optical measurement systems. With 16 years in various executive positions at Siemens Medical Solutions, he led R&D and Operations for the entire portfolio of ultrasonic transducers, including the highly successful AcuNav line of intracardiac echocardiography imaging catheters and the creation of the multi-dimensional family of transducers. Prior to Siemens, Mr. Ho spent 4 years in product development with Quantum Medical Systems, a venture-backed company that pioneered color flow ultrasound and was subsequently acquired by Siemens. Mr. Ho serves on Boards of Directors and as advisor for several medical device companies. He earned a BS and MS degree in Mechanical Engineering from the University of Washington and holds several ultrasound-related patents.

  • John Neis, Director
    Managing Director, Venture Investors LLC

    Mr. Neis is a Managing Director of Venture Investors LLC, an early stage venture capital firm with offices in Madison, Wisconsin and Ann Arbor, Michigan.  The firm’s venture capital funds are focused on opportunities emerging from leading research universities in the Midwest.  John leads the firm and heads the firm’s Health Care practice.  He also currently serves on the Board of Directors of Cellectar BioSciences, Inc., Virent, Inc., Deltanoid Pharmaceuticals, Inc., and Great Lakes Pharmaceuticals, Inc.  He was appointed by the Governor to the Board of the Wisconsin Technology Council, the science and technology advisor to Wisconsin’s Governor and Legislature.  He also serves on the Dean’s Advisory Board and the Weinert Applied Ventures Program Advisory Board in the School of Business and chairs the Tandem Press Advisory Board in the School of Education at the University of Wisconsin – Madison.  He holds a B.S. in finance from the University of Utah, and received a M.S. in Marketing and Finance from the University of Wisconsin – Madison.  He is a Chartered Financial Analyst.

  • Rachel Brem, M.D., Director
    Director, Breast Imaging and Intervention, The George Washington University

    Dr. Brem is one of the nation’s most renowned radiologists and experts on breast imaging and intervention. She is currently the Director, Breast Imaging and Intervention at The George Washington University and the Program Leader, Breast Cancer, at The George Washington Cancer Center. She also serves as the Director of the Breast Imaging and Intervention Fellowship and Vice-Chair for Research and Faculty Development in the Department of Radiology at The George Washington University.

    Dr. Brem is founder of the Brem Foundation to Defeat Breast Cancer, an organization with the mission to maximize women’s chances of finding curable breast cancer through expert education, access to diagnostic tests, and physician training. Dr. Brem played a key role in the development of Computer Aided Design (CAD) and was involved in the first FDA cleared artificial intelligence product for mammography. In addition, she is actively involved in the advancement of Automated Breast Ultrasound Systems (ABUS), Molecular Breast Imaging (MBI) and Magnetic Resonance Imaging (MRI) as supplemental breast imaging modalities.

    Dr. Brem earned her medical degree from Columbia University. She completed her internship in internal medicine at the Sinai Hospital of Baltimore and her residency in radiology at the Johns Hopkins Hospital. She pursued further training in magnetic resonance imaging and breast imaging as a fellow at Johns Hopkins Medical institutions.